- Home
- IMG vs IRD Comparison
IMG vs IRD Comparison
Compare IMG & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMG
- IRD
- Stock Information
- Founded
- IMG 2011
- IRD 2018
- Country
- IMG Hong Kong
- IRD United States
- Employees
- IMG N/A
- IRD N/A
- Industry
- IMG
- IRD
- Sector
- IMG
- IRD
- Exchange
- IMG NYSE
- IRD NYSE
- Market Cap
- IMG 14.7M
- IRD 62.0M
- IPO Year
- IMG 2020
- IRD N/A
- Fundamental
- Price
- IMG $0.27
- IRD $1.02
- Analyst Decision
- IMG
- IRD Strong Buy
- Analyst Count
- IMG 0
- IRD 3
- Target Price
- IMG N/A
- IRD $6.33
- AVG Volume (30 Days)
- IMG 239.4K
- IRD 803.8K
- Earning Date
- IMG 08-18-2025
- IRD 08-15-2025
- Dividend Yield
- IMG N/A
- IRD N/A
- EPS Growth
- IMG N/A
- IRD N/A
- EPS
- IMG N/A
- IRD N/A
- Revenue
- IMG $3,785,663.00
- IRD $13,651,000.00
- Revenue This Year
- IMG $99.05
- IRD $51.41
- Revenue Next Year
- IMG $130.30
- IRD $68.84
- P/E Ratio
- IMG N/A
- IRD N/A
- Revenue Growth
- IMG 109.62
- IRD N/A
- 52 Week Low
- IMG $0.25
- IRD $0.65
- 52 Week High
- IMG $8.00
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- IMG N/A
- IRD N/A
- Support Level
- IMG N/A
- IRD N/A
- Resistance Level
- IMG N/A
- IRD N/A
- Average True Range (ATR)
- IMG 0.00
- IRD 0.00
- MACD
- IMG 0.00
- IRD 0.00
- Stochastic Oscillator
- IMG 0.00
- IRD 0.00
About IMG CIMG INC
CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.